Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state

被引:59
作者
Li, AR
Li, KXZ
Marui, S
Krozowski, ZS
Batista, MC
Whorwood, CB
Arnhold, IJP
Shackleton, CHL
Mendonca, BB
Stewart, PM
机构
[1] UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND
[2] BAKER MED RES INST,MELBOURNE,VIC,AUSTRALIA
[3] UNIV SAO PAULO,HOSP CLIN,ENDOCRINOL UNIT,BR-05508 SAO PAULO,BRAZIL
[4] CHILDRENS HOSP,STEROID LAB,OAKLAND,CA 94609
关键词
glucocorticoid; mineralocorticoid; cortisol; cortisone; 11 beta-hydroxysteroid dehydrogenase; hypertension; molecular genetics;
D O I
10.1097/00004872-199715120-00005
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Apparent mineralocorticoid excess (AME) is a cause of low-renin, low-aldosterone hypertension in which cortisol acts as a mineralocorticoid. The condition reflects an inability to inactivate cortisol to cortisone due to defective activity of the type 2 isozyme of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD2). Homozygous mutations in 11 beta-HSD2 gene in patients with AME have been described. A 7-year-old Brazilian girl had previously been found to have AME. Her father recently presented with mineralocorticoid hypertension at age 38 years. Objective To describe the clinical details, to perform steroid analyses and to assess the molecular basis for the hypertension in this kindred. Methods The 11 beta HSD2 gene was amplified from genomic DNA by the polymerase chain reaction and sequenced by direct chain-termination sequencing on an automatic DNA sequencer. The sequencing results were validated by restriction-site polymorphism. The mutant 11 beta-HSD2 protein was expressed in Chinese hamster ovary polyoma cells and enzymatic activity was assessed by metabolizing cortisol in vitro. Results Sequence analysis of genomic DNA revealed a novel C1061T point mutation in exon V of the human 11 beta-HSD2 gene, resulting in an amino acid substitution of alanine by valine at codon 328 of the enzyme protein (A328V). Expression studies confirmed that the mutant protein was devoid of 11 beta-HSD2 activity. A Hhal restriction-site polymorphism confirmed that the proband was homozygous for the mutation whereas both parents were heterozygotes. The father of the proband had hypertension, a normal serum potassium level, suppressed plasma renin activity and plasma aldosterone level and a moderately elevated urinary cortisol : cortisone metabolite ratio. Conclusions AME in this kindred is caused by a novel mutation in the 11 beta-HSD2 gene. Detection of hypokalaemia, at least in this kindred, is an insensitive screening test for mineralocorticoid-based hypertension. In contrast to results from previously investigated kindreds, we have demonstrated that this kindred has an abnormal phenotype in the heterozygote state. Further studies are now required in order to evaluate the role of 11 beta-HSD2 activity in the pathophysiology of `essential' hypertension.
引用
收藏
页码:1397 / 1402
页数:6
相关论文
共 28 条
[1]   GENE STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN HSD11K GENE ENCODING THE KIDNEY (TYPE-2) ISOZYME OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE [J].
AGARWAL, AK ;
ROGERSON, FM ;
MUNE, T ;
WHITE, PC .
GENOMICS, 1995, 29 (01) :195-199
[2]   CLONING AND TISSUE DISTRIBUTION OF THE HUMAN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2 ENZYME [J].
ALBISTON, AL ;
OBEYESEKERE, VR ;
SMITH, RE ;
KROZOWSKI, ZS .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1994, 105 (02) :R11-R17
[3]   SPIRONOLACTONE-REVERSIBLE RICKETS ASSOCIATED WITH 11-BETA-HYDROXYSTEROID DEHYDROGENASE-DEFICIENCY SYNDROME [J].
BATISTA, MC ;
MENDONCA, BB ;
KATER, CE ;
ARNHOLD, IJP ;
ROCHA, A ;
NICOLAU, W ;
BLOISE, W .
JOURNAL OF PEDIATRICS, 1986, 109 (06) :989-993
[4]   LIDDLES SYNDROME REVISITED - A DISORDER OF SODIUM-REABSORPTION IN THE DISTAL TUBULE [J].
BOTEROVELEZ, M ;
CURTIS, JJ ;
WARNOCK, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (03) :178-181
[5]   NEW FINDINGS IN APPARENT MINERALOCORTICOID EXCESS [J].
DIMARTINONARDI, J ;
STONER, E ;
MARTIN, K ;
BALFE, JW ;
JOSE, PA ;
NEW, MI .
CLINICAL ENDOCRINOLOGY, 1987, 27 (01) :49-62
[6]   LOCALIZATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR [J].
EDWARDS, CRW ;
BURT, D ;
MCINTYRE, MA ;
DEKLOET, ER ;
STEWART, PM ;
BRETT, L ;
SUTANTO, WS ;
MONDER, C .
LANCET, 1988, 2 (8618) :986-989
[7]   FUROSEMIDE INHIBITS 11-BETA-HYDROXYSTEROID DEHYDROGENASE IN-VITRO AND IN-VIVO [J].
ESCHER, G ;
MEYER, KV ;
VISHWANATH, BS ;
FREY, BM ;
FREY, FJ .
ENDOCRINOLOGY, 1995, 136 (04) :1759-1765
[8]   The 11 beta-hydroxysteroid dehydrogenase type II enzyme: Biochemical consequences of the congenital R337C mutation [J].
Ferrari, P ;
Obeyesekere, VR ;
Li, K ;
Andrews, RK ;
Krozowski, ZS .
STEROIDS, 1996, 61 (04) :197-200
[9]   Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess [J].
Ferrari, P ;
Obeyesekere, VR ;
Li, K ;
Wilson, RC ;
New, MI ;
Funder, JW ;
Krozowski, ZS .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1996, 119 (01) :21-24
[10]   MINERALOCORTICOID ACTION - TARGET TISSUE-SPECIFICITY IS ENZYME, NOT RECEPTOR, MEDIATED [J].
FUNDER, JW ;
PEARCE, PT ;
SMITH, R ;
SMITH, AI .
SCIENCE, 1988, 242 (4878) :583-585